Together our results reinforce the role of CLDN1 in the acquired resistance to chemotherapy used in the treatment of CRC and validates the use of our anti-CLDN1 ADC as an alternative for the treatment of refractory CRC patients. The gene discussed is CLDN1; the disease is colorectal carcinoma.